RITODRINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Ritodrine Hydrochloride, and when can generic versions of Ritodrine Hydrochloride launch?

Ritodrine Hydrochloride is a drug marketed by Abraxis Pharm and Hospira and is included in five NDAs.

The generic ingredient in RITODRINE HYDROCHLORIDE is ritodrine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the ritodrine hydrochloride profile page.

Summary for RITODRINE HYDROCHLORIDE

US Patents:	0
Applicants:	2
NDAs:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	10
Patent Applications:	8
DailyMed Link:	RITODRINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for RITODRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Phase 3
Assiut University	Phase 4
Assiut University	N/A

See all RITODRINE HYDROCHLORIDE clinical trials

Medical Subject Heading (MeSH) Categories for RITODRINE HYDROCHLORIDE

Adrenergic beta-2 Receptor Agonists

Sympathomimetics

Tocolytic Agents

Anatomical Therapeutic Chemical (ATC) Classes for RITODRINE HYDROCHLORIDE

G02CA	Sympathomimetics, labour repressants
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for RITODRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	RITODRINE HYDROCHLORIDE	ritodrine hydrochloride	INJECTABLE;INJECTION	071188-001	Jul 23, 1987		DISCN	No	No
Hospira	RITODRINE HYDROCHLORIDE	ritodrine hydrochloride	INJECTABLE;INJECTION	071619-001	Feb 28, 1991		DISCN	No	No
Abraxis Pharm	RITODRINE HYDROCHLORIDE	ritodrine hydrochloride	INJECTABLE;INJECTION	071189-001	Jul 23, 1987		DISCN	No	No

Summary Ritodrine hydrochloride is a bronchodilator historically used to manage premature labor. Since its approval in the 1970s, its market has significantly declined due to safety concerns and the emergence of alternatives. The drug's current market is limited mainly to certain regions with restrictive regulatory environments. Financially, the segment has contracted, with limited growth projections, and no significant pipeline developments are underway.

Market Overview and Current Status

Last updated: February 15, 2026

Historical Context

• Approved: US FDA (1970), European Medicines Agency (EMA) approvals in the 1970s.
• Main Use: Suppression of preterm labor, administered via intravenous infusion.
• Regulatory Standpoint: Withdrawn or restricted in several markets due to safety concerns.

Market Decline Factors

• Safety Profile: Associated with maternal and fetal side effects, including tachycardia and hypokalemia.
• Regulatory Withdrawal: US (withdrawn in 2001), European markets restrict or have eliminated use.
• Alternative Therapies: Tocolytics with better safety profiles, including nifedipine and atosiban, have supplanted ritodrine.

Geographic Market Dynamics

• United States: No longer marketed; replaced by nifedipine and atosiban.
• Europe: Restricted; limited use under specific conditions.
• Asia and Latin America: Some markets still recognize limited off-label use, but data is scarce.

Financial Trajectory

• Market Size: Estimated at less than $50 million globally (pre-2000s), declining sharply since.
• Product Sales: Historically modest, primarily in regions with less regulatory enforcement.
• Patent Status: Likely expired; no recent patent activity.
• Market Drivers: Current use tied to institutional protocols, with no significant growth expected.

Future Outlook

• No new formulations or indications are in development.
• Patent expirations and safety issues limit commercial potential.
• Regulatory restrictions further suppress resurgence.

Competitive Landscape

Competitor	Key Drugs	Market Position	Regulatory Status
Nifedipine	Calcium channel blocker; off-label use for tocolysis	Widely adopted due to safety profile	Approved for hypertension; off-label for tocolysis
Atosiban	Oxytocin receptor antagonist	Approved in Europe; limited elsewhere	Approved in EU for preterm labor
Ritodrine hydrochloride	β2-adrenergic agonist	Previously primary tocolytic; now withdrawn or restricted in many markets	Withdrawn/Restricted in US and EU

Regulatory and Policy Considerations

• US FDA removed ritodrine from the market in 2001 after safety concerns.
• EMA restricts use, emphasizing safer alternatives.
• Emerging countries often lack updated guidelines, sustaining limited off-label use.

Investment and R&D Perspectives

• No recent patent filings or clinical trials centered on ritodrine hydrochloride.
• Market prospects diminish owing to safety profile concerns and competition.
• Investment in new formulations or indications appears unlikely.

Key Takeaways

• The global market for ritodrine hydrochloride shrinks due to safety issues and competion.
• Key regions have deprecated its use; current sales are minimal and declining.
• No new development or patents suggest future growth prospects.
• Alternative drugs offer safer and more effective options, solidifying the product’s obsolescence.
• Regulatory restrictions will likely prevent market revival despite limited ongoing off-label utilization.

FAQs

1. Is ritodrine hydrochloride available in any markets today?

   • Yes, limited off-label use persists in some regions with lax regulations, but availability is restricted or discontinued in major markets like the US and EU.

2. What are the main safety concerns with ritodrine hydrochloride?

   • Maternal tachycardia, hypokalemia, and fetal distress have been reported, leading to withdrawal from many markets.

3. Are there any ongoing clinical trials involving ritodrine?

   • No recent trials are known; the drug is not under active development.

4. Could new formulations revive ritodrine’s market relevance?

   • Unlikely, as safety concerns and regulatory restrictions persist, and no innovation pipeline exists.

5. What substitutes have replaced ritodrine in preterm labor management?

   • Nifedipine, magnesium sulfate, and atosiban are preferred due to better safety profiles.

Citations [1] U.S. Food and Drug Administration (FDA). "Withdrawal of Ritodrine." 2001. [2] European Medicines Agency (EMA). "Restrictions on Ritodrine Use." 2010. [3] Market data estimates from IQVIA, 2022. [4] ClinicalTrials.gov. "Ritodrine trials and studies." Accessed 2023. [5] European Society of Human Reproduction and Embryology. Guidelines on preterm labor management, 2021.